Dernières nouvelles pour Masimo (NASDAQ:MASI) Stock

MASIMO CORP

Masimo

Masimo Corp is a technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.

Masimo Corp

Masivo Silver Corp

Masimo's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NYSE">MASI</a>) short percent of float has risen 3.19% since its last report. The company recently reported that it has 3.13 million shares sold short, which is 8.42% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.12 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Masimo Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750867231_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Masimo has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Masimo's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Masimo's peer group average for short interest as a percentage of float is 4.99%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

MASI

How Do Investors Really Feel About Masimo?

<a href="https://x.com/SarahKarlin/status/1937539272392733011 " title="https://x.com/SarahKarlin/status/1937539272392733011 ">https://x.com/SarahKarlin/status/1937539272392733011&nbsp;</a>

Biotech

General

DXCM

GCTK

SENS

TNDM

WLDS

Watching Stocks Involved In Wearable Health Devices; Traders Circulate X Post Saying "RFK says HHS about to launch one of the biggest campaigns in HHS history to encourage Americans to use wearable health devices (like CGMs). his vision is every American wearing "wearable" in 4 years... HUGE COIs here with some of his top advisors & their businesses."

Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) has outperformed the market over the past 10 years by 4.49% on an annualized basis producing an average annual return of 15.54%. Currently, Masimo has a market capitalization of $9.02 billion. 
Buying $100 In MASI: If an investor had bought $100 of MASI stock 10 years ago, it would be worth $425.41 today based on a price of $167.01 for MASI at the time of writing.
<h3>Masimo's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749736814_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Here's How Much You Would Have Made Owning Masimo Stock In The Last 10 Years

EEG-Guided Anesthesia Using Masimo Technology Significantly Reduced Pediatric Anesthesia Emergence Delirium, Time to Emergence and Discharge, and Cost of Care by Minimizing Sevoflurane Exposure
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.masimo.com&amp;esheet=54271413&amp;newsitemid=20250610391732&amp;lan=en-US&amp;anchor=Masimo&amp;index=1&amp;md5=6d262ad9f7b2d2ff51a19ad3b18cb9e8">Masimo</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) today announced the findings of a randomized clinical trial published in JAMA Pediatrics in which Dr. Yasuko Nagasaka and colleagues at Tokyo Women's Medical University demonstrated the ability of electroencephalogram (EEG)-guided anesthesia, using Masimo SedLine&#xAE; Brain Function Monitoring, to improve anesthesia administration in children undergoing surgery.1 The researchers found that the use of SedLine led to a significant reduction in the amount of a commonly used inhalation anesthetic (sevoflurane) needed to maintain anesthesia in pediatric patients, reducing their exposure to the drug. In turn, the patients experienced a significantly lower rate of pediatric anesthesia emergence delirium, or PAED, which commonly manifests in confusion, agitation, or hallucinations experienced during recovery. When compared with standard practice, children monitored with SedLine also regained consciousness faster and could be safely discharged to the post-anesthesia care unit, or PACU, sooner – time savings that, the researchers noted, may represent additional cost savings. In sum, the researchers found that Masimo SedLine helped to make pediatric anesthesia safer, more efficient, and more cost effective.

Masimo Publishes Findings Of Randomized Clinical Trial In JAMA Pediatrics; Study Shows Ability Of EEG-Guided Anesthesia, Using Masimo Sedline Brain Function Monitoring, To Improve Anesthesia Administration In Children Undergoing Surgery

Masimo Announces Findings In Trial Published In JAMA Pediatrics  Showing EEG-Guided Anesthesia Using Masimo Technology Reduced Pediatric Anesthesia Emergence Delirium, Time To Emergence And Discharge And Cost Of Care

Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) has outperformed the market over the past 15 years by 2.29% on an annualized basis producing an average annual return of 14.41%. Currently, Masimo has a market capitalization of $8.92 billion. 
Buying $100 In MASI: If an investor had bought $100 of MASI stock 15 years ago, it would be worth $779.18 today based on a price of $165.03 for MASI at the time of writing.
<h3>Masimo's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748902514_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Masimo 15 Years Ago Would Be Worth Today

Masimo's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NYSE">MASI</a>) short percent of float has risen 17.24% since its last report. The company recently reported that it has 3.03 million shares sold short, which is 8.16% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.52 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Masimo Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748448024_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Masimo has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Masimo's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Masimo's peer group average for short interest as a percentage of float is 5.21%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Is the Market Bullish or Bearish on Masimo?

Guidance

Masimo To Re-Affirm Updated FY25 Financial Outlook

Raymond James analyst Jayson Bedford maintains Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) with a Outperform and lowers the price target from $204 to $185.

Price Target

Analyst Ratings

Raymond James Maintains Outperform on Masimo, Lowers Price Target to $185

WIIM

Masimo shares are trading lower. The company reported Q1 financial results and announced the sale of its consumer audio business for $350 million.

Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) has outperformed the market over the past 15 years by 1.69% on an annualized basis producing an average annual return of 12.79%. Currently, Masimo has a market capitalization of $8.01 billion. 
Buying $1000 In MASI: If an investor had bought $1000 of MASI stock 15 years ago, it would be worth $6,055.94 today based on a price of $148.31 for MASI at the time of writing.
<h3>Masimo's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746629114_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

Piper Sandler analyst Jason Bednar reiterates Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) with a Overweight and lowers the price target from $215 to $200.

Reiteration

Piper Sandler Reiterates Overweight on Masimo, Lowers Price Target to $200

Wells Fargo analyst Vik Chopra maintains Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) with a Overweight and lowers the price target from $205 to $190.

Wells Fargo Maintains Overweight on Masimo, Lowers Price Target to $190

Masimo Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>), a leading global medical innovator, today announced that it has entered into a definitive agreement to sell its Sound United consumer audio business to HARMAN International ("HARMAN"), a wholly-owned subsidiary of Samsung Electronics Co., Ltd., for an aggregate purchase price of $350 million in cash, subject to certain adjustments. The sale follows the previously announced review of Masimo's consumer audio business and will support the Company's strategic focus on driving innovation in its core professional healthcare segment. The transaction is expected to close by the end of 2025, subject to receiving necessary regulatory approvals.

Masimo Agrees To Sell Sound United Consumer Audio Business To HARMAN International For Aggregate Purchase Price Of $350M In Cash

2025 Outlook For Continuing Operations(4):
<ul>
<li>Non-GAAP revenue of $1,500 to $1,530 million, increasing 8% to 11% on a constant currency basis(3);</li>
</ul>
Excluding the impact of new tariffs (for comparison purposes only to prior guidance, which excluded new tariffs):
<ul>
<li>Non-GAAP operating profit of $420 to $436 million;</li>
<li>Non-GAAP operating margin of 28.0% to 28.5%; and</li>
<li>Non-GAAP earnings per diluted share of $5.30 to $5.60.</li>
</ul>
Updated guidance now includes the impact of new tariffs before any mitigation:
<ul>
<li>Non-GAAP operating profit of $383 to $403 million;</li>
<li>Non-GAAP operating margin of 25.5% to 26.4%; and</li>
<li>Non-GAAP earnings per diluted share of $4.80 to $5.15.</li>
</ul>
We have developed a number of mitigation plans and will continue to reassess and modify our plans as the situation merits. These plans include adjusting our product sourcing and operations to mitigate some of the impact, which is dependent on different tariff scenarios.
________________
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">(1)</td>
<td colspan="1" rowspan="1">The financial information reflects the continuing operations of Masimo's healthcare business.</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(2)</td>
<td colspan="1" rowspan="1">The financial information reflects the Sound United business which is being classified as "held-for-sale" and reported in discontinued operations.</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(3)</td>
<td colspan="1" rowspan="1">Represents a non-GAAP financial measure for which a reconciliation to the most directly comparable GAAP financial measure is included in this earnings release.</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(4)</td>
<td colspan="1" rowspan="1">Represents updated guidance provided May 6, 2025. Financial guidance includes forward-looking non-GAAP financial measures for which reconciliations to the most directly comparable GAAP financial measures are not available without unreasonable efforts. See "Forward-Looking Non-GAAP Financial Measures" within this earnings release, which identifies the information that is unavailable without unreasonable efforts and provides additional information. It is probable that forward-looking non-GAAP financial measures may be materially different from the corresponding GAAP financial measures. Guidance does not include any use of proceeds from a sale of Sound United and/or any potential benefits from new tax policies. Guidance includes the financial impact of one additional calendar week, which occurs every five or six years based on Masimo's 4-4-5 fiscal calendar. Guidance also includes the estimated financial impact of new tariffs (in place as of May 1, 2025), before any mitigation. The implementation of tariffs remains a dynamic and uncertain situation that could cause our actual results to be materially different from our projections and forecasts.</td>
</tr>
</tbody>
</table>
</figure>

Masimo Raises FY2025 Adj EPS Guidance from $5.10-$5.40 to $5.30-$5.60 vs $5.25 Est; Sees Sales $1.500B-$1.530B vs $1.52B Est

Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) reported quarterly earnings of $1.36 per share which beat the analyst consensus estimate of $1.21 by 12.4 percent. This is a 106.06 percent increase over earnings of $0.66 per share from the same period last year. The company reported quarterly sales of $371.00 million which beat the analyst consensus estimate of $367.54 million by 0.94 percent. This is a 24.72 percent decrease over sales of $492.80 million the same period last year.

Earnings

Earnings Beats

Masimo Q1 Adj. EPS $1.36 Beats $1.21 Estimate, Sales $371.00M Beat $367.54M Estimate

ACLS

AHCO

ALAB

ALGS

ALGT

AMTM

ANDE

ANET

ANGI

ARDT

ARIS

ARMK

ARQT

ARRY

ATKR

ATOM

ATRO

AUDC

AVNS

AVNT

AVNW

AZEK

BALL

BBNX

BCAB

BLDP

BRLT

BWIN

BWMN

CCCS

CCLD

CDRE

CELH

CGAU

CGBD

CHMI

CHRD

CIFR

CIGI

CLDT

CLOV

COTY

CPAY

CPIX

CPNG

CRCT

CRIS

CRMD

CRSR

CRUS

CURI

CVGI

CXDO

CYTK

DASH

DAWN

DDOG

DOCN

DRCT

DRVN

DVAX

ENLT

EOSE

Embraer-Empresa Brasileira De Aeronautica

ESPR

EVGO

Earnings Scheduled For May 6, 2025

Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-06. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Masimo to report an earnings per share (EPS) of $1.21.
The announcement from Masimo is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.38, which was followed by a 12.35% increase in the share price the next day.
Here's a look at Masimo's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.42</td>
<td>0.84</td>
<td>0.76</td>
<td>0.69</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.80</td>
<td>0.98</td>
<td>0.86</td>
<td>0.66</td>
</tr>
<tr>
<td>Price Change %</td>
<td>12.0%</td>
<td>11.0%</td>
<td>11.0%</td>
<td>-12.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746453826_0.png" alt="eps graph" />
<h3>Masimo Share Price Analysis</h3>
Shares of Masimo were trading at $166.42 as of May 02. Over the last 52-week period, shares are up 18.75%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Insights Shared by Analysts on Masimo</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Masimo.
Analysts have provided Masimo with 2 ratings, resulting in a consensus rating of Outperform. The average one-year price target stands at $210.0, suggesting a potential 26.19% upside.
<h3>Peer Ratings Comparison</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Globus Medical, Penumbra and Teleflex, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Globus Medical, with an average 1-year price target of $90.4, suggesting a potential 45.68% downside.</li>
<li>Analysts currently favor an Buy trajectory for Penumbra, with an average 1-year price target of $317.0, suggesting a potential 90.48% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Teleflex, with an average 1-year price target of $148.5, suggesting a potential 10.77% downside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
The peer analysis summary presents essential metrics for Globus Medical, Penumbra and Teleflex, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Masimo</td>
<td>Outperform</td>
<td>9.44%</td>
<td>$244.70M</td>
<td>-27.80%</td>
</tr>
<tr>
<td>Globus Medical</td>
<td>Neutral</td>
<td>6.61%</td>
<td>$393.86M</td>
<td>0.64%</td>
</tr>
<tr>
<td>Penumbra</td>
<td>Buy</td>
<td>16.32%</td>
<td>$215.88M</td>
<td>3.32%</td>
</tr>
<tr>
<td>Teleflex</td>
<td>Neutral</td>
<td>-5.04%</td>
<td>$389.44M</td>
<td>2.27%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Masimo ranks highest in Revenue Growth among its peers. It has the lowest Gross Profit margin. Masimo's Return on Equity is negative, indicating lower profitability compared to its peers. Overall, Masimo is positioned differently across the metrics, with strengths in revenue growth but weaknesses in gross profit and return on equity.
<h3>All You Need to Know About Masimo</h3>
Masimo Corp is a technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.
<h3>Breaking Down Masimo's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Masimo's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 9.44% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -58.2%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Masimo's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -27.8%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -12.24%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Masimo's debt-to-equity ratio is below the industry average at 0.8, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/MASI/earnings">To track all earnings releases for Masimo visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Masimo's Earnings: A Preview

Masimo's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NYSE">MASI</a>) short percent of float has fallen 3.59% since its last report. The company recently reported that it has 2.79 million shares sold short, which is 7.53% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.42 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Masimo Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745935223_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Masimo has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Masimo's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Masimo's peer group average for short interest as a percentage of float is 4.06%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Press Releases

Masimo Reports First Quarter 2025 Results

Masimo to Sell Consumer Audio Business to HARMAN International

Masimo to Present in the BofA Securities 2025 Health Care Conference

Legal

MASI INVESTIGATION ALERT: Johnson Fistel PLLP Investigates the Directors and Officers of Masimo Corporation for Breach of Fiduciary Duties

Masimo to Present in the Jefferies Global Healthcare Conference

New Study Finds Masimo SedLine® Brain Function Monitoring Offers Significant Advantages During Pediatric Anesthesia

MASIMO CORPORATION INVESTIGATION ALERT: Johnson Fistel, PLLP Investigates Potential Breach of Fiduciary Duties by Masimo Officers and Directors

Shareholder Alert: Johnson Fistel, LLP Investigates Elanco Animal Health, Masimo, Fidelity National Information, and Super Micro Computer —Long-Term Investors are Encouraged to Contact the Firm

Comments

Masimo

Actualités

Dernières nouvelles pour Masimo (NASDAQ:MASI) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL